Literature DB >> 3146763

Reduction of feeding behavior by the serotonin uptake inhibitor sertraline.

I Lucki1, M S Kreider, K J Simansky.   

Abstract

Administration of the selective serotonin (5-HT) uptake inhibitor sertraline produced a dose-dependent reduction of food intake in rats. Doses of sertraline of 10 mg/kg or greater reduced the intake of solid pellets significantly (P less than 0.01) during the 1st hour of a 4-h feeding test in rats deprived of food and water for 24 h. Food intake during the remaining 3 h and water intake during the feeding test was unaffected by sertraline. Sertraline (2-18 mg/kg IP) also reduced milk consumption in food-deprived rats. Pretreatment with the nonselective 5-HT antagonists metergoline (2 mg/kg IP) or methysergide (3.3 mg/kg IP) blocked sertraline's inhibition of dry food intake, whereas pretreatment with the selective 5-HT2 receptor antagonist ketanserin (3.3 mg/kg IP) or the peripheral 5-HT2 antagonist xylamidine (2.5 mg/kg IP) failed to block sertraline's anorexic effect. The feeding-suppressant effect of 10 mg/kg sertraline was prevented following the destruction of central 5-HT neurons by the 5-HT neurotoxic agent, 5,7-dihydroxytryptamine (200 micrograms ICV). This result is consistent with sertraline's anorexic effect depending on intact 5-HT neurotransmission. Therefore, sertraline appears to reduce feeding by enhancing the action of endogenous serotonin at central synapses mediated by 5-HT1 rather than 5-HT2 receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146763     DOI: 10.1007/bf00216052

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Dissociation of the anorectic actions of 5-HTP and fenfluramine.

Authors:  P J Fletcher; M J Burton
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Studies on food intake of genetically obese rats.

Authors:  G A Bray; D A York
Journal:  Am J Physiol       Date:  1972-07

3.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats.

Authors:  R W Fuller; H D Snoddy; N R Mason; J E Owen
Journal:  Neuropharmacology       Date:  1981-02       Impact factor: 5.250

4.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

5.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

Authors:  J E Leysen; C J Niemegeers; J M Van Nueten; P M Laduron
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

6.  Peripherally administered serotonin decreases food intake in rats.

Authors:  J D Pollock; N Rowland
Journal:  Pharmacol Biochem Behav       Date:  1981-08       Impact factor: 3.533

7.  Suppression of milk drinking by the combination of fluoxetine and L-5-hydroxytryptophan in rats.

Authors:  R W Fuller; J E Owen
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-10

8.  Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.

Authors:  N W Pedigo; H I Yamamura; D L Nelson
Journal:  J Neurochem       Date:  1981-01       Impact factor: 5.372

9.  Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats.

Authors:  R Samanin; T Mennini; A Ferraris; C Bendotti; F Borsini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

10.  1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats.

Authors:  L E Schechter; K J Simansky
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  16 in total

1.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

2.  Effects of chronically administered fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence.

Authors:  J McGuirk; R Muscat; P Willner
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test.

Authors:  S Wieland; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  The role of serotonin in eating disorders.

Authors:  S F Leibowitz
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Role of serotonin receptors in the effect of sertraline on feeding behaviour.

Authors:  G Grignaschi; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

Review 8.  The use of lorcaserin in the management of obesity: a critical appraisal.

Authors:  Bo Bai; Yu Wang
Journal:  Drug Des Devel Ther       Date:  2010-12-20       Impact factor: 4.162

9.  Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.

Authors:  T Mennini; A Bizzi; S Caccia; A Codegoni; C Fracasso; E Frittoli; G Guiso; I M Padura; C Taddei; A Uslenghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

Review 10.  Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.